Objective: To determine the effect of folic acid, vitamin B 6 and B 12 fortified spreads on the blood concentrations of these vitamins and homocysteine. Design and setting: A 6-week randomized, double-blinded, placebo-controlled, parallel trial carried out in a clinical research center. Subjects: One hundred and fifty healthy volunteers (50% males). Interventions: For 6 weeks, the subjects consumed the test spreads (20 g/day): containing per 20 g (1) 200 mg folic acid, 2 mg vitamin B 12 and 1 mg vitamin B 6 , or (2) 400 mg folic acid, 2 mg vitamin B 12 and 1 mg vitamin B 6 or (3) no B-vitamins (control spread). Results: The B-vitamin status increased on using the test spreads, with the largest effect on the serum folate concentration: 48% in men and 58% in women on spread 1 and 92 and 146%, respectively, on spread 2 (P-values all o0.05). The plasma homocysteine decreased in the groups treated with the fortified spreads as compared to the control group. Average decreases were for males: 0.771.5 mmol/l (6.8%) on spread 1 and 1.771.7 mmol/l (17.6%) on spread 2 and for females: 1.471.2 mmol/l (14.2%) and 2.472.0 mmol/l (23.3%), respectively (P-values all o0.05). Conclusions: Consumption of a spread fortified with folic acid, vitamin B 6 and vitamin B 12 for 6 weeks significantly increases the blood concentrations of these vitamins and significantly decreases the plasma concentration of homocysteine. Fortified staple foods like spreads can contribute to the lowering of homocysteine concentrations.
Introduction
Cardiovascular disease (CVD) is the single largest cause of death in industrialized Western countries (WHO/FAO, 2003) . Total plasma homocysteine (tHcy) concentration is emerging as an independent and graded risk factor for atherosclerotic vascular disease; a large meta-analysis indicated that a prolonged difference of a 25% lower tHcy concentration is associated with a 10% lower risk of coronary heart diseases and a 20% lower risk of stroke (The Homocysteine Studies Collaboration, 2002; Wald et al., 2002) .
Homocysteine is an intermediary product in methionine metabolism. The metabolic breakdown of homocysteine to cysteine occurs via a vitamin B 6 -dependent reaction. Alternatively, homocysteine can be (re)methylated to methionine using folate as a methyl donor in a vitamin B 12 -dependent reaction (Selhub and Miller, 1992) .
In the general population, large groups do not consume enough B-vitamins for an optimal homocysteine status (Selhub et al., 1993; de Bree et al., 1997) . In addition, folate and vitamin B 12 deficiencies are relatively common in the elderly (Clarke et al., 2004) . There are three ways to increase the intake of B-vitamins: increasing the intake of B-vitaminrich foods, supplements and fortified foods. Giving supplements with folic acid (synthetic form of folate) alone, or in combination with vitamin B 6 and vitamin B 12 , to subjects with normal (Ward et al., 1997; Brouwer et al., 1999a) or elevated baseline tHcy concentrations (Brattstrom et al., 1988; Olszewski et al., 1989; Ubbink et al., 1993 Ubbink et al., ,1994 Wald et al., 2001) , will lower the tHcy concentration by about 32% (Homocysteine Lowering Trialists' Collaboration, 2005) . Staple foods could be a better carrier for delivering B-vitamins to the general population than supplements. A spread seems a suitable vehicle for these vitamins as the daily intake is relatively constant and does not fluctuate greatly between subjects. This ensures controlled delivery of the B-vitamins while minimizing the risk of overconsumption. The objective of the present study was to determine the effect of a spread fortified with folic acid, vitamin B 6 and vitamin B 12 on the blood concentrations of these B-vitamins and on the tHcy concentration.
Subjects and methods

Subjects
The study was conducted according to Good Clinical Practice at TNO Nutrition and Food Research (Zeist, The Netherlands). The TNO Medical Ethics Committee approved the protocol.
Apparently healthy subjects were recruited from a pool of volunteers registered at the Institute (not including TNO employees) and by advertisement in local newspapers. All volunteers gave written informed consent before they underwent a screening procedure that included a health and lifestyle questionnaire, a physical examination and a routine blood clinical chemistry profile. A total of 150 subjects (75 males and 75 females) were included in the study. Eligible subjects were between 18 and 70 years of age and had a body mass index (BMI) between 19 and 30 kg/m 2 . They did not suffer from diagnosed CVD, high blood pressure (according to WHO guidelines) (Guidelines Subcommittee, 1999) and/or high plasma tHcy concentration (420 mmol/l). They were not using medication that could interfere with the study outcome (e.g. malaria prophylaxis, anti-convulsants), were not on a prescribed diet and did not use dietary (vitamin) supplements, yeast and/or seaweed products in the month before the screening. Females reported an alcohol intake of o22 glasses/week and males of o29 glasses/week. Finally, all subjects had average Dutch eating habits, including spread consumption.
Study design
The study was a randomized, placebo-controlled, doubleblind parallel study. The subjects included were stratified by gender and plasma tHcy concentration and then randomly assigned to one of the three spreads. Each group had to consume 20 g spread/day for 6 weeks. The study spreads contained per 20 g: (1) 200 mg folic acid, 2 mg vitamin B 12 and 1 mg vitamin B 6 , or (2) 400 mg folic acid, 2 mg vitamin B 12 and 1 mg vitamin B 6 or (3) no B-vitamins (control). Subjects and TNO personnel were blinded, except for the statistician responsible for treatment allocation and the dietitian responsible for labeling the spreads. Subjects visited the research center once every 2 weeks. Spreads were supplied (and returned) per 2-week period, a well-being questionnaire was filled in at every visit, and blood was sampled at visits 1, 3 and 4 (i.e. the first day and after 4 and 6 weeks).
The study spreads were intended to replace an equivalent amount of the habitually used spread. Subjects were provided with portion packs for a period of 2 weeks: one per day and two spare portions (16 in total). They were instructed to store the spreads in a refrigerator. To ensure that all the spread was consumed, the subjects were instructed to use it on bread and not for frying and/or baking. Compliance to the consumption of 20 g of spread per day was estimated based on the used and non-used portion packs returned every 2 weeks. In addition, subjects were asked to register daily the consumption of the spread. The returned packs were weighed and non-used spread was calculated. In the case that a pack was not returned, but claimed to be consumed, the pack was assumed to be consumed. For each 2-week period, the subjects had to consume 280 g of spread, and compliance per period was calculated as a percentage of those 280 g.
Subjects were not allowed to use (vitamin) supplements in the months before screening (5-2 weeks before start of the study). During the study, subjects used a self-selected diet but were instructed not to use (vitamin) supplements from the screening day onwards until the end of the study, and to consume certain products (a list was provided) like liver, yeast and seaweed (products) not more than once a week. In addition, these products were not allowed during 48 h before blood collection. Subjects were also advised not to change their dietary habits during the study. At the time of the study, folic acid fortified foods were not allowed in the Dutch market.
Blood was collected after an overnight fast for at least 10 h on days 1, 29 and 43, respectively of the treatment period. To obtain information about the habitual folate, vitamin B 12 and vitamin B 6 intake, a food frequency questionnaire (FFQ) with B125 items was handed out to subjects on day 1 to be completed and returned by post before day 15. The dietitian checked the FFQ with the subject on day 15.
Adverse events were evaluated by the medical investigator on the basis of a well-being questionnaire filled in by the subjects at each 2-weekly visit.
Spreads
The fortified spreads were prepared by Unilever Bestfoods (URDV), Vlaardingen, the Netherlands. The spreads were fortified with folic acid (pteroylglutamic acid (Folacin), Roche, Switzerland), vitamin B 12 (cyanocobalamine, Roche, Switzerland) and vitamin B 6 (pyridoxine hydrochloride, Roche, Switzerland). The folic acid content per 20 g spread was 19578 mg for test spread 1 and 441729 mg for test spread 2. Actual vitamin B 6 and vitamin B 12 contents were as planned: 2.170.05 mg B 12 and 1.070.02 mg B 6 per 20 g of spread. The total fat content and the fatty acid composition of the spread was similar to that of a low-fat spread (39%) with a high polyunsaturated fatty acid content.
B-vitamins are normally found in aqueous environments, as they are water-soluble. The stability of the B-vitamins in an oily formulation like a spread was tested in several shelf life experiments. These indicated that at 51C, and at higher temperatures, the vitamin B 6 and vitamin B 12 content remain stable over a period of 12 weeks. The folic acid content decreased over 12 weeks by B15% (5-27%). During normal manufacturing procedures, losses are taken into account, and averaging is applied to guarantee that the amount of B-vitamins as declared on the pack is still present at the end of the shelflife. This procedure was also applied to the spreads used in this trial.
Blood handling and analyses
Blood was collected from the antecubital vein using Vacutainer tubes. To obtain serum, blood was collected in tubes containing clot activator. Blood samples were centrifuged 15-30 min after collection for 10 min at ca. 2000 Â g at ca. 41C. After centrifugation, serum was removed, mixed and divided over the aliquots needed, and stored at À181C.
To obtain plasma, ethylenediaminetetraacetic acid (ED-TA)blood was collected. Immediately after collection, the blood was mixed and stored in a cool place. Samples were centrifuged within 30 min after collection for 10 min at ca. 2000 Â g at 41C. Within 30 min after centrifugation, plasma was removed mixed and divided over the aliquots needed, and stored at À181C.
All analyses were performed in samples collected on days 1, 29 and 43 unless indicated otherwise. Hematology (RBC, WBC, platelets, Ht, Hb, mean corpuscular volume (MCV) was determined in whole blood. Total cholesterol, highdensity lipoprotein (HDL)-cholesterol, after precipitation with polyethylene glycol, and triacylglycerols were determined in serum of days 1 and 43 using the commercial test kits (Boehringer, Mannheim, Germany) on a Hitachi 911 automatic analyzer (Hitachi Instrument Division, Ibaraki-ken, Japan). Serum low-density lipoprotein (LDL)-cholesterol concentration was calculated using the formula by Friedewald et al. (1972) .
Folate was measured in fasting serum samples and in whole blood samples. Folates were measured using a competitive protein (affinity) binding assay with the commercial reagent kit (Simultrac Radioassay kit, ICN Pharmaceuticals Diagnostic Division, Orangeburg NY, USA). This assay is based upon the method originally described by Dunn and Foster (1973) , and modified by Givas and Gutcho (1975) . Whole blood folate was measured using the same procedure after 10-fold dilution of whole blood with a 1% ascorbate solution pH 4.5; 0.1% bovine serum albumin (BSA) solution pH 6.5 and pre-incubation of the lysate to allow deconjugation of the polyglutamate forms present in the erythrocyte, by the endogenous serum deconjugase enzyme, as described earlier (Wright et al., 2000) .
Vitamin B 6 was measured in plasma samples, by highperformance liquid chromatography (Schrijver et al., 1981) . Vitamin B 12 was measured in serum samples, using the SimulTRAC Radioassay Kit (ICN Pharmaceuticals Diagnostic Division, Orangeburg, NY, USA).
Plasma tHcy was measured in plasma samples, using HPLC with fluorescence detection as described by Accinni et al. (1998) . After chemical reduction with tributylphosphine, homocysteine was derivatized with ammonium 7-fluoro 2,1,3,benzoxadiazole-4-sulfonate (SBD-F). The resulting derivate was detected fluorimetrically.
The analyses of the samples were carried out when all samples had been collected and with all samples of one subject in the same run. Intra-assay CVs for the B-vitamins and tHcy were o5%, and the inter-assay CVs were o6.5%.
Food frequency questionnaire
For this study, TNO developed an FFQ to obtain specific information on intake of folate and vitamin B 6 . To select the relevant questions for this purpose, calculations were made using the sub-population of males and females, between 18 and 70 years, of the 2nd Dutch National Food Consumption Survey of 1992 (Lowik et al., 1998) . To the list based on folate and vitamin B 6 , products known to be rich in vitamin B 12 were added, if not incorporated yet.
To estimate the folate intake, a TNO database was used (Brants and Hulshof, 1995) , based mainly on information from the 5th edition of the English food composition table (Holland et al., 1991) . To estimate the vitamin B 6 intake, the Dutch Food Composition Table ( NEVO, 1996) was used. To estimate the vitamin B 12 intake, data were based on a report from the Wageningen University (Heijden et al., 1997) .
With the data of the Dutch National Food Consumption Survey (Lowik et al., 1998) , the FFQ used in the present study was estimated to cover approximately 90% of folate intake and 94% of vitamin B 6 intake in the Dutch population. We were not able to calculate the vitamin B 12 coverage, as data on the B 12 intake was not available in this survey.
Statistical analysis
For all blood parameters for each individual, both absolute and relative (%) changes were calculated by subtracting the value obtained on day 1 from the value obtained on day 29 or 43.
The study design was based on a combined power analysis for males and females , indicating that 50 subjects per group were needed to demonstrate a 1 mmol/l treatment effect on homocysteine as compared to control. Taking into account a possible difference between genders, males and females were distributed equally over the treatment groups. Preliminary statistical analyses showed significantly different concentrations between males and females for some parameters and Effect of fortified spread on homocysteine concentration T van Vliet et al also a significant interaction between treatment and gender. Therefore, it was decided to stratify the statistical analyses per measurement day for males and females separately. Looking back, the study was also adequately powered for these separate analyses. This can be explained by the actual treatment effects being greater than 1 mmol/l on homocysteine and the s.d. values being slightly lower than assumed for the power calculation previously.
Statistical analyses were carried out with SAS statistical software package SAS/STAT (version 6.12, SAS Institute, Cary, NC, USA). All parameters were normally distributed and expressed as the mean7s.d. Treatment effects were investigated using analysis of variance (using the general linear model procedure as implemented in SAS). If the analysis indicated an overall treatment effect (Po0.05), comparisons between treatment means were performed using a two-sided Student's t-test. Within each treatment group, changes were evaluated over time by comparing results obtained on days 1, 29 and 43 using paired t-tests. Because of multiple comparisons in these analyses without an overall test, a Bonferroni correction was applied. This means that for these analyses only P-values o0.0167 (0.05/3) were considered statistically significant.
The study was unblinded after reporting of the adverse events and after evaluation and statistical analysis of all biochemical data.
Results
A total of 149 volunteers completed the study. One subject discontinued because of a serious adverse event that was not related to the treatment. Two subjects were excluded from all statistical analyses and group data, because essential data were missing. Thus, results are presented for 147 subjects (75 males and 72 females). Non-essential data were missing for three subjects who are included in data analyses. The actual number of subjects available for each parameter is indicated in the respective tables and figures.
Selected characteristics of the study population are presented in Table 1 . The level of traditional CVD risk factors (BMI, blood pressure and cholesterol fractions) was typical of an apparently healthy population. The tHcy concentration was higher in men than in women, and the same was true of the habitual intake of B-vitamins.
Compliance with the consumption of 20 g of spread per day was excellent, with an average per treatment group 0-4% of spread not consumed during the first 2 weeks, and only 0-1% in the following 4 weeks. Compliance did not differ between treatments and genders. Subjects reported the use of spreads with bread, with only six incidental exceptions. Only eight subjects reported use of liver, yeast and seaweed (products) more than once a week, or within 48 h before blood collection, each subject on one occasion only.
Based on the adverse event reporting, three possible side effects occurred. One subject receiving spread 1 experienced flatulence and more liquid faeces, both of a mild intensity, starting at day 2 and that was still present at day 43. Another subject receiving spread 2 experienced a disturbance of taste with a mild intensity (when eating spread), from day 8 until day 42.
With two exceptions, baseline B-vitamin concentrations did not differ between treatment groups (see Table 2 ). In females, the mean serum folate concentration was lower in the group receiving spread 2 as compared to the control group (P ¼ 0.005), and for males the mean plasma vitamin B 6 concentration was lower in the group receiving spread 1 as compared to those who consumed spread 2 (P ¼ 0.008). 
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Serum folate concentration increased significantly with 48 and 92% in males receiving spread 1 and spread 2, respectively, resulting in mean serum folate concentrations after 6 weeks of treatment of 22.1 and 29.8 nmol/l, respectively. For females, increases were 58 and 146%, resulting in mean serum folate concentrations after 6 weeks of treatment of 23.9 and 30.2 nmol/l and after treatment with spread 1 and spread 2, respectively. For both males and females, increases after consumption of spread 2 were significantly greater than after spread 1. Erythrocyte folate concentration increased significantly with 15 and 24% in males receiving spread 1 and spread 2, respectively, resulting Effect of fortified spread on homocysteine concentration T van Vliet et al in mean erythrocyte folate concentrations after 6 weeks of treatment of 1522 and 1607 nmol/l, respectively. For females, increases were 17 and 37%, resulting in mean erythrocyte folate concentrations after 6 weeks of treatment of 1473 and 1572 nmol/l, after treatment with spread 1 and spread 2, respectively. Only for females, increases after consumption of spread 2 were significantly greater than after spread 1. The folate concentrations in the control group remained similar over the intervention period (Table 2 , Figures 1 and 2) . Results for plasma vitamin B 6 and serum vitamin B 12 are presented in Table 2 . Plasma vitamin B 6 concentrations increased significantly after consumption of the fortified spreads with 49 and 37% in males to concentrations of 79 and 101 nmol/l after 6 weeks of consumption of spread 1 and spread 2, respectively. For females, increases were 45 and 57% to values of 75 and 77 nmol/l, respectively.
Serum vitamin B 12 concentrations also increased significantly after consumption of the fortified spreads, with 17 and 20% in males to concentrations of 308 and 311 pmol/l after 6 weeks of consumption of spread 1 and 2, respectively. For females increases were 15 and 26% to values of 298 and 311 nmol/l, respectively. There were no differences in the vitamin B 6 and vitamin B 12 content of spread 1 and spread 2, which was reflected in the absence of differences in the vitamin B 6 and vitamin B 12 concentration between the groups taking spread 1 and spread 2.
Baseline concentrations for tHcy within each gender did not differ between treatment groups. Figure 3 and Table 2 present the results for the plasma tHcy concentration over the intervention period per treatment group and gender. The tHcy concentration in males decreased in the groups receiving the fortified spreads with 6.8 and 17.6% to concentrations of 9.8 and 8.7 mmol/l after 6 weeks of consumption of spread 1 and spread 2, respectively. For females decreases were 14.2 and 23.3% to values of 7.9 and 6.8 mmol/l, respectively. For both males and females, decreases after consumption of spread 2 were significantly greater than after spread 1.
Changes of serum total and HDL-cholesterol from day 1 to day 43 were not different between treatments (data not shown). No significant changes in hematology parameters were observed (data not shown).
Discussion
This study showed that consumption of a spread fortified with folic acid, vitamin B 6 and B 12 for 6 weeks increases significantly the blood concentrations of those compounds 
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and decreases the concentration of tHcy in a dose-dependent way. Earlier intervention trials (Ward et al., 1997; Brouwer et al., 1999a) have shown that the lowering effect of folic acid supplementation on the plasma tHcy concentration depends on the baseline tHcy concentration. Therefore, we stratified our treatment groups on plasma tHcy concentrations at screening. In addition, we stratified for gender, which resulted in similar baseline tHcy concentrations in the treatment groups within males and females. The stratification for gender turned out to be justified, as we observed a larger homocysteine-lowering effect in females than in males, occurring in spite of lower mean baseline tHcy concentrations in females. Differences in homocysteine metabolism between the genders may explain this as males have a lower remethylation rate as compared to females (Fukagawa et al., 2000) . Another explanation could be the differences in lean body mass (Norlund et al., 1998) or the hormonal status (Andersson et al., 1992; Giltay et al., 1998) .
Habitual dietary intake of the B-vitamins does not seem to explain the gender difference. The intake was about 10% lower for females than for males, but comparable between treatment groups (Table 1 ). The intake of the B-vitamins was similar to that reported in earlier Dutch studies Brussaard et al., 1997; de Bree et al., 2001a) . From this it follows that the baseline concentrations of plasma tHcy, vitamin B 6 and vitamin B 12 as well as serum folate were within expected ranges and comparable with those reported in other studies in countries without a folic acid fortification program (Ward et al., 1997; Nygard et al., 1998; Rasmussen et al., 2000) .
The only remaining factor that may explain the gender difference is smoking. Approximately 28% of the males and 23% of the females in this study were smokers. Smoking is positively associated with the tHcy concentration (Nygard et al., 1995; Giles et al., 1999; Rasmussen et al., 2000; Jacques et al., 2001; Koehler et al., 2001; de Bree et al., 2001b) . The exact mechanism behind the increase in the tHcy concentration is unidentified, but it cannot be explained merely by a lower intake of B-vitamins in smokers (Piyathilake et al., 1992; Pryor and Stone, 1993; Mansoor et al., 1995; Bergmark et al., 1997; Blom, 1998) . Although we cannot exclude the possibility that smoking could have interfered with the response to folic acid supplementation, it is unlikely that smoking affected the study results, as subjects were stratified on screening tHcy and smokers were distributed almost evenly over the treatment groups (except for a somewhat lower number of female smokers in the group that received spread 1).
Compared to other studies that tested the effect of folic acid fortified foods, the increase in serum folate appeared to be somewhat lower in our study, whereas on the other hand, the increase in erythrocyte folate and the decrease in tHcy was larger (Riddell et al., 2000; Johansson et al., 2002; Vahteristo et al., 2002; Ashfield-Watt et al., 2003; Carrero et al., 2004; Tapola et al., 2004; Tucker et al., 2004) . Apart from the dose used, these differences can be explained by variations in study protocols, duration of the intervention and by the carrier of the vitamins (e.g. breakfast cereals, water, bread, juice etc.). However, such comparisons are complicated by still existing, largely unexplained differences in assay methodology for blood folates, resulting in a relatively large interlaboratory variation (Gunter et al., 1996) .
In an earlier study, it has already been shown that a spread fortified with 200 mg of folic acid acutely improves the folate status (Pentieva et al., 2003) , but to our knowledge no other long-term experiment has been carried out with a fortified spread. Data are scarce on the effect of vitamin B 6 and vitamin B 12 fortified foods, but our results are in line with these data (Tapola et al., 2004; Tucker et al., 2004) .
Comparing the two doses applied in the present study, it seems that providing a higher daily dose (spread 2, 442 mg folic acid) results in a more rapid increase in serum and erythrocyte folate concentration as compared to spread 1 (198 mg folic acid). In addition, the serum and erythrocyte folate concentration on spread 2 increased further between days 29 and 43, indicating that a steady state had not been reached during the 6-week study period. It seems probable that this state was reached in subjects taking spread 1 with the lower folic acid dose. However, the tHcy concentrations (as well as concentrations of vitamin B 6 and vitamin B 12 ) Effect of fortified spread on homocysteine concentration T van Vliet et al seemed to have stabilized within 6 weeks for both spreads. Although we cannot exclude the possibility that the tHcy status would have changed further if we had continued the trial after 6 weeks, only limited further decreases can be expected with the dosages applied (Riddell et al., 2000; van Oort et al., 2003) , and thus the high dose was more effective than the low dose. This finding is confirmed by the findings of an elegant dose-response study showing a dosedependent decrease of tHcy and indicating that a daily dose of X400 mg of folic acid is needed for a maximum reduction of tHcy (van Oort et al., 2003) . However, the most effective dose is not necessarily the same as the optimal (adequate and safe) fortification level. For selection of an optimal dose several other factors play a role, like potential intake of fortified products and the target population for a product, which is beyond the scope of this paper.
As has been described in the introduction, a relatively large part of the population does not have optimal B-vitamin intakes to maintain a low tHcy concentration (Selhub et al., 1993; de Bree et al., 1997) . Even worse, among the elderly, a large percentage has a biochemical vitamin B deficiency (Clarke et al., 2004) . There are three ways to improve the B-vitamin status in the population: increasing the intake of B-vitamin-rich foods, of supplements and of fortified foods. Increasing the intake of B-vitamin-rich food (cereal products, vegetables and fruits) has the advantage of increasing the intake of a lot of other important food components, and thus should always be promoted. The increased intake of vegetables and citrus fruits has indeed been proved to be successful in improving folate status and lowering tHcy concentrations (Brouwer et al., 1999b; Ruggeri et al., 2003) . However, as it does not seem feasible to attain the relatively large amounts of those foods needed for optimal intakes in the general population, additional measures might be necessary. Supplements have proved effective (Clarke and Armitage, 2000) , but individuals need to remember to take a supplement. From this perspective fortified food products may play a more important role as it is impossible to forget intake, provided fortification is mandatory or subjects actually choose the fortified products. In general, this makes fortified products an easy and effective option to improve the B-vitamin status and to lower the tHcy concentration (Cuskelly et al., 1996; Riddell et al., 2000) . This study shows that a fortified spread could be a good means to achieve this improvement.
In summary, this study shows that spreads fortified with B-vitamins effectively improve the B-vitamin can status and lower the tHcy concentration in 6 weeks, with a larger effect on a higher dose, spread. Mandatory fortification with folic acid is not allowed in most European countries. In addition, in those countries where voluntary fortification is permitted, the range of products is limited. Adding spreads to this range will broaden the proportion of the population that can benefit from this effective source. Improving the B-vitamin status can have important health consequences, as a higher B-vitamin intake may prevent not only CVD, which is the major cause of death in industrialized countries, but also other serious health conditions such as birth defects, cognitive decline and cancer (Lucock, 2004) .
